• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on Actuate Therapeutics with a new price target

    3/17/25 7:17:09 AM ET
    $ACTU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACTU alert in real time by email
    H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00
    Get the next $ACTU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACTU

    DatePrice TargetRatingAnalyst
    4/22/2025$21.00Buy
    Craig Hallum
    3/17/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACTU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bios Equity Cof, Lp bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27, sold $224,991 worth of shares (24,999 units at $9.00) and converted options into 9,380,699 shares (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:54:46 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fletcher Aaron G.L. converted options into 9,380,699 shares, bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27 and sold $224,991 worth of shares (24,999 units at $9.00) (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:49:12 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Kreis Leslie W. converted options into 9,380,699 shares, bought $4,000,000 worth of shares (500,000 units at $8.00), exercised 37,951 in-the-money shares at a strike of $5.27 and sold $224,991 worth of shares (24,999 units at $9.00) (SEC Form 4)

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      8/14/24 8:44:04 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACTU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

      - Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone - Patients with liver metastases experienced a 2.5x improvement in 1-year OS with a 38% reduction in risk of death when treated with elraglusib plus GnP CHICAGO and FORT WORTH, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the in

      6/24/25 9:15:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

      CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced biomarker data from a recent poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC). The study demonstrated the use of machine learning an

      6/20/25 8:45:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

      Inclusion reflects continued growth and momentum in the company's mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced today that the Company will be added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, effective after the U.S. market close on June 27, as part of the 2025 Rus

      6/16/25 8:30:00 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACTU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Thomson Todd S

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      5/23/25 4:37:19 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sawhney Roger

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      5/23/25 4:05:33 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Keyes Jason A

      4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)

      5/23/25 4:05:28 PM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACTU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Actuate Therapeutics with a new price target

      Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00

      4/22/25 8:00:39 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Actuate Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00

      3/17/25 7:17:09 AM ET
      $ACTU
      Biotechnology: Pharmaceutical Preparations
      Health Care